Action over generic Lipitor may subject FDA to congressional probe

12/2/2012 |

The FDA's disclosure that a shortage of a generic version of cholesterol drug Lipitor is "not anticipated" may be an invitation for Congress to take up work on the drug-shortage legislation and investigate the FDA for allowing Ranbaxy Laboratories to produce and sell a generic Lipitor, RPM Report's Michael McCaughan said. Ranaxby's issues with production raise questions whether the FDA bargained hard enough if patient safety and the supply chain's integrity were the top goals.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT